McKinsey's plan to turbocharge OxyContin sales
Even after Purdue Pharma pleaded guilty in 2007 to misbranding OxyContin, McKinsey kept advising it on how to 'turbocharge' sales, including by targeting high-prescribing doctors. In 2017 McKinsey consultants floated the idea that Purdue pay distributors a rebate, estimated at about $14,000, for each customer who overdosed on opioids they had sold. In 2021 McKinsey paid roughly $573 million to settle claims by U.S. states over its opioid work, without admitting wrongdoing.